Abstract
Objectives To determine whether spontaneous reporting rates of myocarditis and pericarditis differed in immunocompromised patients compared to the whole population overall, and in terms of demographics, vaccine dose, and time-to-onset.
Design Systematic review of spontaneously reported data from the European Union/European Economic Area (EU/EEA), the United States (US) and the United Kingdom (UK).
Data Sources EudraVigilance (EU/EEA), Vaccine Adverse Event Reporting System (VAERS; US) and the Medicines and Healthcare products Regulatory Agency (MRHA, UK) spontaneous reporting databases were searched from date of vaccine launch to 01 December 2021.
Eligibility criteria Publicly available spontaneous reporting data for “Myocarditis” and “Pericarditis” from EU/EEA and US following COVID-19 mRNA vaccines. Reports with comorbidities or concurrent medication indicative of transplantation, HIV infection, or cancer (“immunocompromised” population) were compared with each overall database population.
Data extraction and synthesis Two researchers extracted data. Spontaneously reported events of myocarditis and pericarditis were presented for immunocompromised populations for each data source, stratified by age, sex, dose, and time-to-onset (where available). Seriousness of each event was determined according to the ICH E2A definition. Proportional Reporting Ratio (PRR) was calculated.
Results There were 178 reports of myocarditis and pericarditis amongst immunocompromised individuals overall. Seriousness was comparable between the immunocompromised and overall populations in both databases. No trends in age or sex were observed amongst immunocompromised individuals. Most reports followed a second vaccine dose and occurred within 14 days. The frequency of reporting was similar to the wider population (PRR=1.36 [95% CI= 0.89-1.82] for VAERS population).
Conclusions Myocarditis and pericarditis following COVID-19 vaccination are very rare, and benefits of COVID-19 vaccination continue to outweigh any perceived risks. Reporting rates of myocarditis and pericarditis were similar in immunocompromised individuals, however defining characteristics differed compared to the whole population; therefore, continued monitoring of adverse events following vaccination remains vital to understand differences between population subgroups.
Strengths and Limitations of the Study
This is the first study to investigate the frequency and characteristics of reported events of myocarditis and pericarditis in immunocompromised individuals compared with the population as a whole, bringing together data from three regions (Europe, the United States, and the United Kingdom).
Results from this study demonstrate that myocarditis and pericarditis are not more frequently reported following COVID-19 mRNA vaccines for immunocompromised individuals, however age and sex distributions are less clear, and clinical course may differ compared with the overall population.
As with all analyses using spontaneously reported data, results may have been subject to underreporting and missing information, including information on comorbidities and concomitant medications. It is possible that some immunocompromised were incorrectly classified as immunocompetent. Further biases may have influenced results, including differences in vaccination strategies between the two regions examined, differences in data collected via spontaneous reporting systems, and serious events more likely to be reported.
It is not possible to estimate incidence rates using spontaneous reports due to a lack of data on the exposed population, and there is no unexposed comparison group.
Further monitoring of myocarditis and pericarditis events in immunocompromised populations is needed as booster vaccination programmes progress. Pharmacoepidemiological studies are urgently needed to provide more accurate estimates of the frequency and clinical course of myocarditis and pericarditis following COVID-19 mRNA vaccination amongst immunocompromised people.
Competing Interest Statement
All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: The Drug Safety Research Unit (DSRU) is a registered independent charity (No. 327206) associated with the University of Portsmouth. The DSRU receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford/AstraZeneca COVID-19 vaccine and is in negotiations to receiving grants for conducting CPRD studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit-risk studies on products for COVID-19, including remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford/AstraZeneca vaccine in Europe. Samantha Lane and Alison Yeomans have no conflicts of interest with regard to this study.
Funding Statement
No external funding was received for the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Systematic searches of spontaneous reporting outputs of the European Union/European Economic Area (EU/EEA; EudraVigilance) and the United States (US; Vaccine Adverse Event Reporting System [VAERS] via CDC Wonder tool) were used in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version includes additional data from the United Kingdom population provided by the Medicines and Healthcare products Regulatory Agency (MHRA), which strengthens the conclusions drawn.
Data Availability
All data produced in the present work are contained in the manuscript
